A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

NCT01031225 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

113

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: STA 9090

Sponsor

Synta Pharmaceuticals Corp.